Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TM4SF1-positive chimeric antigen receptor T-cell therapy
- Development stage
- Unknown
- Lead developer
- Shanghai Ultra-T Immune Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
TM4SF1-positive chimeric antigen receptor T-cell therapy (also known as CART-TM4SF1) is an investigational autologous CAR-T cell therapy developed by Changhai Hospital of Shanghai in collaboration with Shanghai Ultra-T Immune Therapeutics. The therapy targets Transmembrane 4 L Six Family Member 1 (TM4SF1), a plasma membrane glycoprotein that is highly expressed in various digestive system cancers, including pancreatic, colorectal, gastric, and liver cancers, as well as on the vascular endothelial cells lining tumor blood vessels. By targeting TM4SF1, the engineered T-cells aim to eliminate tumor cells and inhibit tumor angiogenesis. The CAR construct includes an epidermal growth factor receptor (EGFR)-based safety switch to allow for the selective depletion of the CAR-T cells if necessary. It is currently being evaluated in Phase 1 clinical trials for patients with recurrent or refractory advanced TM4SF1-positive digestive system tumors.
- Other names
- TM4SF1-directed chimeric antigen receptor T cellsTM-4SF1-directed chimeric antigen receptor T cellsTM 4SF1-directed chimeric antigen receptor T cells
02
Targets
EGFRt (Epidermal growth factor receptor (truncated))TM4SF1 (Transmembrane 4 L6 family member 1)
Beyond the preview
Go deeper on TM4SF1-positive chimeric antigen receptor T-cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TM4SF1-positive chimeric antigen receptor T-cell therapy.